WO2011122477A1 - ベシクル含有組成物 - Google Patents
ベシクル含有組成物 Download PDFInfo
- Publication number
- WO2011122477A1 WO2011122477A1 PCT/JP2011/057378 JP2011057378W WO2011122477A1 WO 2011122477 A1 WO2011122477 A1 WO 2011122477A1 JP 2011057378 W JP2011057378 W JP 2011057378W WO 2011122477 A1 WO2011122477 A1 WO 2011122477A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vesicle
- silicone
- water
- oil
- containing composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 104
- -1 polyoxyethylene Polymers 0.000 claims abstract description 79
- 229920001296 polysiloxane Polymers 0.000 claims abstract description 76
- 239000004094 surface-active agent Substances 0.000 claims abstract description 63
- 239000003945 anionic surfactant Substances 0.000 claims abstract description 40
- 229920002545 silicone oil Polymers 0.000 claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 24
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical class NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000003012 bilayer membrane Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 52
- 229940079593 drug Drugs 0.000 claims description 49
- 238000002156 mixing Methods 0.000 claims description 41
- 238000004519 manufacturing process Methods 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 claims description 13
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 13
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 13
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 11
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 11
- 229960000401 tranexamic acid Drugs 0.000 claims description 11
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 10
- 229930195712 glutamate Natural products 0.000 claims description 10
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 8
- 235000010323 ascorbic acid Nutrition 0.000 claims description 7
- 239000011668 ascorbic acid Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 5
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- SKQOTPRMPUYWSH-FQEVSTJZSA-N CCCCCCCCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC(O)=O Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC(O)=O SKQOTPRMPUYWSH-FQEVSTJZSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- 229940072107 ascorbate Drugs 0.000 claims description 4
- 229940071124 cocoyl glutamate Drugs 0.000 claims description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 4
- 229960004889 salicylic acid Drugs 0.000 claims description 4
- 238000013329 compounding Methods 0.000 claims description 3
- 229940071136 stearoyl glutamate Drugs 0.000 claims description 3
- 229940104261 taurate Drugs 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 235000021317 phosphate Nutrition 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 42
- 235000019198 oils Nutrition 0.000 description 42
- 239000002537 cosmetic Substances 0.000 description 22
- 230000008859 change Effects 0.000 description 20
- 239000008346 aqueous phase Substances 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 239000013011 aqueous formulation Substances 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 9
- 229940049906 glutamate Drugs 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000004205 dimethyl polysiloxane Substances 0.000 description 6
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 229960003080 taurine Drugs 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 239000003346 palm kernel oil Substances 0.000 description 4
- 235000019865 palm kernel oil Nutrition 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 239000003760 tallow Substances 0.000 description 4
- 230000007332 vesicle formation Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- RKJGFHYCZPZJPE-UHFFFAOYSA-N 2,2-bis(16-methylheptadecanoyloxymethyl)butyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(CC)(COC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C RKJGFHYCZPZJPE-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- SWQUTKGVXGTROS-UHFFFAOYSA-N bis(2-ethoxyethyl) butanedioate Chemical compound CCOCCOC(=O)CCC(=O)OCCOCC SWQUTKGVXGTROS-UHFFFAOYSA-N 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940119676 diethoxyethyl succinate Drugs 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008384 inner phase Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- YRJKYHIIYRGTCC-UHFFFAOYSA-M potassium;2-hydroxy-4-methoxybenzoate Chemical compound [K+].COC1=CC=C(C([O-])=O)C(O)=C1 YRJKYHIIYRGTCC-UHFFFAOYSA-M 0.000 description 2
- 229940118594 trimethylolpropane triisostearate Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- BJDAUCLANVMIOB-UHFFFAOYSA-N (3-decanoyloxy-2,2-dimethylpropyl) decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)(C)COC(=O)CCCCCCCCC BJDAUCLANVMIOB-UHFFFAOYSA-N 0.000 description 1
- KZRXPHCVIMWWDS-AWEZNQCLSA-N (4S)-4-amino-5-dodecanoyloxy-5-oxopentanoic acid Chemical compound CCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC(O)=O KZRXPHCVIMWWDS-AWEZNQCLSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- HANWHVWXFQSQGJ-UHFFFAOYSA-N 1-tetradecoxytetradecane Chemical compound CCCCCCCCCCCCCCOCCCCCCCCCCCCCC HANWHVWXFQSQGJ-UHFFFAOYSA-N 0.000 description 1
- DHGBAFGZLVRESL-UHFFFAOYSA-N 14-methylpentadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C DHGBAFGZLVRESL-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- GACXBUWTQZRDBM-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)propane-1,3-diol;2,2,3,3-tetraethylhexanoic acid Chemical compound OCC(CO)(CO)CO.CCCC(CC)(CC)C(CC)(CC)C(O)=O GACXBUWTQZRDBM-UHFFFAOYSA-N 0.000 description 1
- DGSZGZSCHSQXFV-UHFFFAOYSA-N 2,3-bis(2-ethylhexanoyloxy)propyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(OC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DGSZGZSCHSQXFV-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N 2-Ethylhexanoic acid Chemical compound CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- AYUKNFXLSTVUAB-UHFFFAOYSA-N 2-[2-[2-(2,2-dimethylpropanoyloxy)propoxy]propoxy]propyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OC(C)COC(C)COC(C)COC(=O)C(C)(C)C AYUKNFXLSTVUAB-UHFFFAOYSA-N 0.000 description 1
- CMJUNAQINNWKAU-KTKRTIGZSA-N 2-[[(z)-2-oxononadec-10-enyl]amino]ethanesulfonic acid Chemical class CCCCCCCC\C=C/CCCCCCCC(=O)CNCCS(O)(=O)=O CMJUNAQINNWKAU-KTKRTIGZSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- KKDLMTFRMQVLMO-UHFFFAOYSA-N 2-heptylundecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CCCCCCC)CCCCCCCCC KKDLMTFRMQVLMO-UHFFFAOYSA-N 0.000 description 1
- JVXJFNLEXLGQIO-UHFFFAOYSA-N 2-hexyldecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CCCCCC)CCCCCCCC JVXJFNLEXLGQIO-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QFQVFSLIWFWHSC-UHFFFAOYSA-N 6-(2-heptylundecoxy)-6-oxohexanoic acid Chemical compound CCCCCCCCCC(CCCCCCC)COC(=O)CCCCC(O)=O QFQVFSLIWFWHSC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RDOFJDLLWVCMRU-UHFFFAOYSA-N Diisobutyl adipate Chemical compound CC(C)COC(=O)CCCCC(=O)OCC(C)C RDOFJDLLWVCMRU-UHFFFAOYSA-N 0.000 description 1
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- SUZRRICLUFMAQD-UHFFFAOYSA-N N-Methyltaurine Chemical class CNCCS(O)(=O)=O SUZRRICLUFMAQD-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229920004482 WACKER® Polymers 0.000 description 1
- XKMYWNHZAQUEPY-YZGJEOKZSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 12-hydroxyoctadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCC(O)CCCCCC)C1 XKMYWNHZAQUEPY-YZGJEOKZSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- DRRMRHKHTQRWMB-UHFFFAOYSA-N [3-(2-ethylhexanoyloxy)-2,2-bis(2-ethylhexanoyloxymethyl)propyl] 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(COC(=O)C(CC)CCCC)(COC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DRRMRHKHTQRWMB-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- HGKOWIQVWAQWDS-UHFFFAOYSA-N bis(16-methylheptadecyl) 2-hydroxybutanedioate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CC(O)C(=O)OCCCCCCCCCCCCCCCC(C)C HGKOWIQVWAQWDS-UHFFFAOYSA-N 0.000 description 1
- WMNULTDOANGXRT-UHFFFAOYSA-N bis(2-ethylhexyl) butanedioate Chemical compound CCCCC(CC)COC(=O)CCC(=O)OCC(CC)CCCC WMNULTDOANGXRT-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- SHZIWNPUGXLXDT-UHFFFAOYSA-N caproic acid ethyl ester Natural products CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 229940031769 diisobutyl adipate Drugs 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- VJHINFRRDQUWOJ-UHFFFAOYSA-N dioctyl sebacate Chemical compound CCCCC(CC)COC(=O)CCCCCCCCC(=O)OCC(CC)CCCC VJHINFRRDQUWOJ-UHFFFAOYSA-N 0.000 description 1
- 229940090934 diphenylsiloxy phenyl trimethicone Drugs 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 229940074774 glycyrrhizinate Drugs 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- IROBLZDPARQMAB-UHFFFAOYSA-N hexadecan-7-yl octanoate Chemical compound CCCCCCCCCC(CCCCCC)OC(=O)CCCCCCC IROBLZDPARQMAB-UHFFFAOYSA-N 0.000 description 1
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 description 1
- PMMXXYHTOMKOAZ-UHFFFAOYSA-N hexadecyl 7-methyloctanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCC(C)C PMMXXYHTOMKOAZ-UHFFFAOYSA-N 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940071085 lauroyl glutamate Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical compound C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 239000008385 outer phase Substances 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229960003339 sodium phosphate Drugs 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- UKSFMDODPANKJI-UHFFFAOYSA-M sodium;2-[methyl(octadecanoyl)amino]ethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)N(C)CCS([O-])(=O)=O UKSFMDODPANKJI-UHFFFAOYSA-M 0.000 description 1
- QKHBMQWPOUUMQZ-BDQAORGHSA-M sodium;hydron;(2s)-2-(octadecanoylamino)pentanedioate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC([O-])=O QKHBMQWPOUUMQZ-BDQAORGHSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
- A61K8/894—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone modified by a polyoxyalkylene group, e.g. cetyl dimethicone copolyol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Definitions
- the present invention relates to the improvement of vesicle stability to vesicle-containing compositions, in particular to high concentration formulations of water-soluble drugs thereof.
- amphiphilic compounds having both hydrophilic and hydrophobic properties for example, phospholipids and the like which form spherical vesicles composed of a bilayer membrane (lamellar layer) in an aqueous phase is there.
- Such bilayer vesicles are called liposomes or vesicles, and these can stably retain an aqueous component inside the vesicle or an oil component inside the vesicle membrane.
- it is used as microcapsules in the fields of medicine, cosmetics, food and the like, from the advantages of, for example, retaining a drug and administering it in vivo and maintaining the drug effect over a long period of time.
- a composition having good appearance (transparency) and feel in use can be obtained by forming liposomes or vesicles, use as a base of cosmetics is also expected.
- silicone-based surfactants have been known as amphiphilic compounds capable of forming such vesicles. While vesicle formation with silicone surfactants is easier than using other surfactants, it is particularly cosmetic in that it is difficult to maintain stability due to aging or temperature and to stably blend perfume ingredients.
- vesicle-containing compositions have been proposed in which these have been improved.
- Patent Document 1 the presence of a water-soluble low molecular weight surfactant (anionic surfactant) in the external phase of a vesicle comprising a silicone-based surfactant allows the vesicle to withstand use as a cosmetic base. It is disclosed that stability is given.
- an oil component containing a silicone oil and a flavor is mixed in advance, then the outer mixture is mixed with an ethanol solution of a silicone surfactant, and mixed with an aqueous formulation to form vesicles.
- the perfume can be retained within the bilayer membrane of the vesicles.
- a water-soluble drug such as tranexamic acid may be blended in an effective amount or more.
- a water-soluble drug such as tranexamic acid
- the present invention has been made in view of the problems of the prior art, and an object thereof is to provide a vesicle-containing composition having excellent stability in the presence of a water-soluble drug.
- the vesicle-containing composition according to the present invention is selected from (A) silicone surfactant, (B) polyoxyethylene alkyl (12 to 15) ether phosphate, acylmethyl taurine salt, and acyl glutamate salt.
- anionic surfactants 0.001 to 0.2% by weight of one or more anionic surfactants, (C) polar oil and / or silicone oil having an IOB of 0.05 to 0.80, and (D) a composition And 0.5 to 5% by weight of water containing a water-soluble drug, wherein (A) the silicone surfactant forms vesicles, and (B) the anionic surfactant adheres to the surface of the vesicles. And (C) polar oil and / or silicone oil are present in the bilayer membrane of the vesicle.
- the anionic surfactant is selected from polyoxyethylene alkyl (12 to 15) ether phosphoric acid, stearoylmethyl taurine salt, cocoyl glutamate, and stearoyl glutamate. It is preferable that it is a species or more.
- the water-soluble drug (D) is selected from the group consisting of tranexamic acid and its derivative, salicylic acid and its salt, alkoxysalicylic acid and its salt, ascorbate and its derivative, glycine and its derivative It is preferable that it is at least one selected from the group consisting of
- the silicone surfactant (A) is a polyoxyalkylene-modified silicone represented by the following general formula (1).
- R 1 is hydrogen or an alkyl group having 1 to 6 carbon atoms.
- A is at least one of the groups represented by the formula:-(CH 2 ) a- (C 2 H 4 O) b- (C 3 H 6 O) c -R 2 wherein R 2 is hydrogen or an alkyl group having 1 to 6 carbon atoms, a is 1 to 6, b is 0 to 50, c is an integer of 0 to 50, and b + c Is a polyoxyalkylene group represented by at least 5), and the other A is hydrogen or an alkyl group having 1 to 6 carbon atoms, m is an integer of 1 to 200, and n is an integer of 0 to 50. .)
- the blending amount of (C) IOB of 0.05 to 0.80 of
- the vesicle formed by the silicone surfactant further comprises (E) 0.001 to 0.05% by mass of sodium metabisulfite and / or 0.005 to 0. It is preferred to contain 05% by weight of dibutylhydroxytoluene.
- water containing 0.5 to 5% by mass of a water-soluble drug based on the composition (D) further comprises ethanol, propylene glycol, dipropylene glycol and 1,3-butylene glycol It is preferable to contain one or more selected from the group.
- the method for producing a vesicle-containing composition comprises mixing of (A) a silicone surfactant and (C) an oily component including a polar oil and / or a silicone oil having an IOB of 0.05 to 0.80. (D) mixed with a mixture of aqueous components including water including a water soluble drug, and (B) selected from polyoxyethylene alkyl (12-15) ether phosphate, acyl methyl taurine salt, and acyl glutamate salt It is characterized by adding and mixing one or more anionic surfactants.
- the present invention it is possible to obtain a composition containing highly stable vesicles under the formulation of a water-soluble drug. As a result, it becomes possible to blend various water-soluble drugs in a sufficient amount with respect to a cosmetic or the like using vesicles made of silicone surfactant, and to further impart functions.
- the vesicle-containing composition according to the present invention comprises (A) a silicone surfactant, and (B) one or more anionic compounds selected from polyoxyethylene alkyl (12 to 15) ether phosphate and acylmethyl taurine salts. 0.001 to 0.2% by weight of surfactant, (C) polar oil of 0.05 to 0.80 IOB, and 0.5 to 5% by weight of water soluble drug to (D) composition And (A) the silicone surfactant forms vesicles, (B) the anionic surfactant adheres to the surface of the vesicles, and (C) the polar oil and / or the silicone oil comprises the vesicles.
- the present invention is characterized in that it is present in a bilayer membrane of
- the (A) silicone-based surfactant used in the present invention is not particularly limited as long as it is a surfactant having a polysiloxane structure as a hydrophobic group.
- Specific examples of the silicone surfactant (A) include polyoxyalkylene modified silicones represented by the following general formula (1).
- R 1 is hydrogen or an alkyl group having 1 to 6 carbon atoms.
- A is at least one of the groups represented by the formula:-(CH 2 ) a- (C 2 H 4 O) b- (C 3 H 6 O) c -R 2 wherein R 2 is hydrogen or an alkyl group having 1 to 6 carbon atoms, a is 1 to 6, b is 0 to 50, c is an integer of 0 to 50, and b + c Is a polyoxyalkylene group represented by at least 5), and the other A is hydrogen or an alkyl group having 1 to 6 carbon atoms, m is an integer of 1 to 200, and n is an integer of 0 to 50. .)
- R 1 is a side chain in the polysiloxane structure of the main chain and is hydrogen or an alkyl group having 1 to 6 carbon atoms. Also, they may be the same or different. For example, when all R 1 s are methyl groups, a dimethylpolysiloxane structure is obtained, and when they are methyl groups and phenyl groups, a methylphenylpolysiloxane structure is obtained.
- A is a position where a polyoxyalkylene group can be introduced in the main-chain polysiloxane structure, and at least one of them is a group of the formula:-(CH 2 ) a- (C 2 H 4 O) b- (C 3 H 6 O) c -R 2 wherein R 2 is hydrogen or an alkyl group having 1 to 6 carbon atoms, a is 1 to 6, b is 0 to 50, and c is an integer of 0 to 50, b + c is a polyoxyalkylene group represented by at least 5).
- the other A when a part of A is the polyoxyalkylene group, the other A may be hydrogen or an alkyl group having 1 to 6 carbon atoms.
- the two terminal A's are polyoxyalkylene groups, it is a polyoxyalkylene-modified silicone represented by the type ABA.
- the polyoxyalkylene group may be any of a polyoxyethylene group, a polyoxypropylene group, and a polyoxyethylene / polyoxypropylene group.
- M representing the number of moles of the unsubstituted polysiloxane structure is 1 to 200
- n representing the number of moles of the polyoxyalkylene-substituted polysiloxane structure is 0 to 50.
- n 0, one or both of the two terminal A's need to be a polyoxyalkylene group.
- silicone surfactant (A) used in the present invention polyoxyethylene (12 moles) modified dimethylpolysiloxane (a side chain methyl group of linear dimethylpolysiloxane is 12) pendant type polyoxyalkylene modified silicone substituted by a group, polyoxyethylene (8 mole) modified dimethylpolysiloxane, polyoxyethylene (20 mole) modified dimethylpolysiloxane and the like.
- polyoxyethylene 8 mole modified dimethylpolysiloxane polyoxyethylene (20 mole) modified dimethylpolysiloxane and the like.
- ABA type polyoxyethylene-methylsiloxane-polyoxyethylene block copolymers and the like.
- it is desirable that the molecular weight of ethylene oxide in the total molecular weight is 20 to 60%.
- the silicone surfactant (A) used in the present invention can also be produced by a known method, or a commercially available product may be used.
- examples of commercially available silicone surfactants include SH3772M, SH3773M, and SH3775M (all manufactured by Dow Corning Silicone Co., Ltd.), IM-22 (manufactured by Wacker Chemical Co.), and the like. Further, these (A) silicone surfactants may be used alone or in combination of two or more.
- the silicone surfactant is a component of a vesicle, and is contained as a vesicle in the vesicle-containing composition according to the present invention.
- the formation of vesicles can be easily carried out by a known method as described later as the production method of the present invention, for example, (A) silicone surfactant and optionally ethanol, propylene glycol in an aqueous formulation By mixing and stirring one or more selected from dipropylene glycol and 1,3-butylene glycol, it is possible to form a vesicle comprising (A) silicone surfactant in an aqueous formulation.
- the particle diameter of the vesicle is not particularly limited, but is usually about 20 to 500 nm, preferably 50 to 200 nm.
- the HLB of the silicone surfactant (A) is not particularly limited, but is preferably 4 to 12 and more preferably 6 to 9 from the viewpoint of formation of vesicles. If the HLB of the silicone surfactant (C) deviates from the above range, it becomes difficult to form stable vesicles, and (C) oil components containing polar oil can not be efficiently incorporated into the vesicle bilayer membrane. is there.
- the blending amount of the silicone surfactant (A) is not particularly limited as long as it can form vesicles, but is preferably 0.1 to 10% by mass with respect to the total amount of the composition, More preferably, it is 0.2 to 5.0% by mass.
- the blending amount of the silicone surfactant (A) is small, the effect of vesicle formation may not be obtained. On the other hand, when the blending amount is too large, the stability of the vesicle may be poor.
- Anionic surfactants which can be used in the present invention The agent is preferably a polyoxyethylene alkyl (12 to 15) ether phosphoric acid, an acylmethyl taurine salt and / or an acyl glutamate salt represented by the following general formula (2).
- R 1 is an alkyl group having 12 to 15 carbon atoms.
- R 2 and R 3 are each independently R 4 O (CH 2 CH 2 O) m-1 OH 2 CH 2 -or a hydrogen group.
- R 4 is an alkyl group having 12 to 15 carbon atoms, and m and n representing the addition mole number of oxyethylene are integers such that the sum is 1 to 30.
- polyoxyethylene alkyl (12 to 15) ether phosphoric acid for example, polyoxyethylene (10 mol) lauryl ether, polyoxyethylene (3 mol) myristyl ether, polyoxyethylene (7 mol) dodecyl ether, etc.
- DDP-2, NIKKOL TDP-10 all manufactured by Nikko Chemicals Co., Ltd.
- acyl methyl taurine salt coconut oil fatty acid methyl taurine salt, palm kernel oil fatty acid methyl taurine salt, hardened palm kernel oil fatty acid methyl taurine salt, beef tallow fatty acid methyl taurine salt, hardened beef tallow fatty acid methyl taurine salt, caproyl methyl taurine Salts, lauroyl methyl taurine salt, myristoyl methyl taurine salt, palmitoyl methyl taurine salt, stearoyl methyl taurine salt, oleoyl methyl taurine salt, cocoyl methyl taurine salt and the like can be mentioned.
- acyl glutamate stearoyl glutamate, cocoyl glutamate, coconut oil fatty acid glutamate, lauroyl glutamate, coconut oil fatty acid glutamate, palm kernel oil fatty acid glutamate, hardened palm kernel oil fatty acid glutamate, beef tallow fatty acid glutamate And salts of hardened tallow fatty acid glutamate and the like.
- Preferred counter ions of the above-mentioned salts include Na, K, triethanolamine, ammonia and the like.
- at least one member selected from polyoxyethylene alkyl (12 to 15) ether phosphoric acid, stearoyl methyl taurine salt, cocoyl glutamate salt, and stearoyl glutamate salt may be used as the component (B).
- NIKKOL SMT manufactured by Nikko Chemicals Co., Ltd.
- Amisoft CK-22, Amisoft HS-11P (F) manufactured by Ajinomoto Co., Ltd.
- the (B) anionic surfactant is believed to adhere to the surface of the vesicle formed by the (A) silicone surfactant and to protect the vesicle from damage due to the formulation of the water soluble drug. Therefore, (B) anionic surfactant protects the outer surface of the vesicle by adding it to the system after forming vesicles with (A) silicone surfactant in water containing (D) water-soluble drug. ⁇ Can contribute to stabilization. When (B) anionic surfactant is added at the time of formation of the vesicle, the protective effect of the vesicle by the same component may be insufficient.
- the compounding quantity of (B) anionic surfactant is not restrict
- a polar oil and / or a silicone oil as the oil component.
- the blending of polar oil and / or silicone oil having an IOB of 0.05 to 0.80 is preferable. If only the polar oil having an IOB value of more than 0.80 is used without blending the oil, the stability of the vesicles becomes insufficient.
- the polar oil having an IOB of 0.05 to 0.80 is not particularly limited as long as it is preferably an oil component having an IOB value within the above range.
- the IOB value of the oil component can be calculated by a known calculation method based on the structure.
- polar oils include, for example, isostearic acid, isopropyl myristate, cetyl octanoate, octyldodecyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, myristyl myristate, decyl oleate Hexyldecyl octanoate, isononyl isononanoate, cetyl lactate, myristyl lactate, lanolin acetate, isocetyl stearate, isocetyl isostearate, cetyl ethylhexanoate, cholesteryl 12-hydroxystearate, ethylene glycol di-2-ethylhexanoate, Pentaerythritol fatty acid ester, N-alkyl glycol monoisostearate, neopentyl glycol dicaprate, diisostearic acid
- the silicone oil used in the present invention is not particularly limited as long as it is an oily component having a polysiloxane structure, and any linear or cyclic structure, or volatile or non-volatile one may be used. Absent. Specific examples of silicone oils include linear silicones such as dimethylpolysiloxane, methylphenylpolysiloxane and methylhydrogenpolysiloxane, cyclic silicones such as octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane. A silicone etc. are mentioned and these can be used combining 1 type, or 2 or more types arbitrarily, combining.
- volatile cyclic silicone oils in particular, octamethylcyclotetrasiloxane and decamethylcyclopentasiloxane can be suitably used.
- volatile cyclic silicone oils By using these volatile cyclic silicone oils, it is possible to incorporate more perfume ingredients into the vesicle bilayer membrane, and it is less sticky and excellent when the vesicle-containing composition is used as an external preparation. A feeling of use is obtained.
- the non-volatile silicone oil it is particularly preferable to use a low viscosity silicone oil such as diphenylsiloxyphenyl trimethicone and methylpolysiloxane.
- the blending amount of the (C) polar oil and / or the silicone oil is preferably 0.001 to 0.3% by mass in total with respect to the total amount of the composition.
- IOB is not polar oil such as polar oil other than 0.05 to 0.80, mineral oil, etc. It is also possible to use oil together.
- composition of the present invention is formulated with water containing a water soluble drug.
- the stability of the vesicles with silicone surfactants is usually lowered by the presence of a water-soluble drug of 0.5% by mass or more, but in the present invention, the vesicles are protected with (B) anionic surfactant. Therefore, high stability can be maintained even in the presence of a water-soluble drug.
- the blending amount of the water-soluble drug in the vesicle-containing composition according to the present invention is 0.5 to 5% by mass with respect to the total amount of the composition.
- an upper limit of less than 0.5% by mass may fail to blend an effective amount of the drug.
- the drug can not be introduced into the vesicle inner phase at a concentration of 0.5% or more, vesicles may not be sufficiently used as microcapsules in conventional vesicle-containing compositions. Even in such a case, with the vesicle-containing composition of the present invention, a water-soluble drug can be blended in a wide concentration range while maintaining the stability of the vesicle.
- the water-soluble drug used in the present invention is not limited as long as it is a water-soluble drug applicable to pharmaceuticals, quasi-drugs, cosmetics and the like, but, for example, inositol, pyridoxine hydrochloride, nicotinamide, ascorbic acid magnesium phosphate Ascorbic acid sodium phosphate, pantothenic acid, pantothenic acid, vitamins such as biotin, arginine hydrochloride, aspartate, cystine, cysteine, methionine, serine, leucine, tryptophan, alanine, glycine, trimethylglycine, glutamate, Anti-inflammatory agents such as cysteine hydrochloride, glycylglycine etc., glycyrrhizinic acid, glycyrrhizinate, glycyrrhetinic acid, azulene etc., alkoxysalicylic acid, alkoxysalicylic acid, tranexa
- tranexamic acid and its derivatives it is particularly preferred to be selected from the group consisting of tranexamic acid and its derivatives, salicylic acid and its salts, alkoxysalicylic acid and its salts, ascorbate and its derivatives, glycine and its derivatives.
- these water-soluble drugs can be blended one or two or more in combination.
- a formulation containing tranexamic acid, tranexamic acid methylamide hydrochloride, 4-methoxysalicylic acid potassium salt, ascorbic acid glucoside, ethyl vitamin C is particularly preferable.
- the amount of water Water is not particularly limited, preferably 70 to 95% by weight, based on the total amount of the composition, more preferably 80 to 90 mass%. When the amount of water is small, vesicles may not be formed.
- any aqueous component generally used for pharmaceuticals, cosmetics and the like may be compounded in water in such a range that the stability of the vesicles is not affected.
- polystyrene resin examples include ethylene glycol, propylene glycol, 1,3-butylene glycol, tetramethylene glycol, glycerin, sorbitol, diethylene glycol, dipropylene glycol, tetramethylene glycol, diglycerin, polyethylene glycol, polypropylene glycol and the like. Particularly, propylene glycol, dipropylene glycol and 1,3-butylene glycol are preferable.
- ethanol and one or more aqueous components selected from the above-mentioned polyols can be blended in an amount of 1 to 20% by mass, preferably 3 to 10% by mass, based on the total amount of the composition.
- the blending amount is less than the above-described amount, the odor suppressing effect is not sufficiently exhibited. If the blending amount is exceeded, the odor due to sodium pyrosulfite or the discoloration due to dibutylhydroxytoluene may occur.
- sodium metabisulfite and / or dibutylhydroxytoluene exerts the effect of suppressing the odor change of the silicone surfactant.
- the effect is a remarkable effect that was first found by the present inventors, and sodium metabisulfite and / or dibutylhydroxytoluene is a silicone-based composition in a vesicle-containing composition produced using a silicone-based surfactant. It functions as an odor control agent that suppresses the odor change derived from the surfactant.
- the vesicle-containing composition according to the present invention can be produced using the above-mentioned essential components (A) to (D).
- a publicly known method can be applied to the method for producing the vesicle-containing composition, and for example, (A) silicone-based surfactant and (C) IOB are polar oils of 0.05 to 0.80 and / or Or mixing of an oily component containing silicone oil, mixing it with (D) a mixture of water containing a water soluble drug and an optional aqueous component, and further adding and mixing (B) a specific anionic surfactant
- the composition of the present invention can be obtained by
- vesicles are formed by mixing the aqueous formulation and the silicone surfactant.
- the aqueous formulation is (D) water containing a water-soluble drug to which any aqueous component is added.
- a vesicle comprising the silicone surfactant is formed in the aqueous phase, and the IOB mixed with the silicone surfactant is 0.05 to 0.
- An oily component comprising .80 polar oil and / or silicone oil is incorporated into the bilayer membrane of the vesicles.
- the anionic surfactant When a specific anionic surfactant is added to the thus obtained vesicle-containing aqueous solution, the anionic surfactant forms micelles around the vesicle bilayer membrane. It is thought that the micelles present (adhered) outside the vesicle greatly contribute to the stabilization of the vesicle membrane. In addition, since vesicles are formed in advance by the above-mentioned process, the anionic surfactant can not penetrate into the inner phase of the vesicle, and the micelle composed of the anionic surfactant is substantially added to the outer phase of the vesicle. Will only exist.
- micelles composed of the anionic surfactant are added by adding the specific anionic surfactant to the vesicle-containing aqueous solution previously formed by mixing the aqueous formulation and the silicone surfactant. Substantially exists only in the external phase of the vesicle, which results in improved stability of the vesicle.
- the regular structure of the vesicle bilayer which can form the silicone surfactant can be obtained.
- the anionic surfactant compounded at the same time may directly affect the formation of vesicles.
- the anionic surfactant may be present in both the internal phase and the external phase of the vesicle, and the desired vesicle stabilization effect may not be obtained.
- This mixture is mixed with a mixture obtained by mixing a predetermined amount of (E) sodium metabisulfite and / or dibutylhydroxytoluene and (D) water containing a water-soluble drug and an optional aqueous component, and (B) a specific anion
- the vesicle-containing composition of the present invention can be produced by adding and mixing an organic surfactant.
- the vesicle-containing composition according to the present invention can be suitably used, for example, as a cosmetic.
- the formulation components usually used for cosmetics, medicines, quasi-drugs, etc. are appropriately blended in a blending amount within a range that does not affect vesicle formation and its stability. can do.
- the other formulation components may be appropriately blended in the oil component mixture or in the aqueous formulation before or after vesicle formation.
- the use of the cosmetic composition according to the present invention is not particularly limited, for example, it can be suitably used as a cosmetic solution, a cosmetic solution, a hair liquid and the like.
- the present invention will be described in more detail by way of examples of the present invention, but the present invention is not limited thereto.
- the compounding amount is expressed in mass%.
- the appearance stability of the vesicle-containing composition obtained by the formulation and manufacturing method shown in Table 1 below was evaluated.
- the evaluation method of external appearance stability is as follows.
- the vesicle-containing compositions of Test Examples 1-1 and 1-2 in which a specific anionic surfactant (stearoyl methyl taurine sodium) is blended, have a water-soluble drug content of 0.5% by mass or more ( In the presence of tranexamic acid, it showed excellent stability at both storage temperatures of 50 ° C and -10 ° C.
- the vesicle-containing compositions of Test Examples 1 to 3 and 1 to 4 in which another anionic surfactant (POE (2) sodium lauryl ether carboxylate) is blended are stable when the water-soluble drug is not blended.
- the appearance stability of the vesicle-containing composition obtained by the formulation and manufacturing method shown in Table 2 below was evaluated.
- the evaluation method of the appearance stability is as described above.
- (* 1) SH3773M, manufactured by Dow Corning Silicone (* 2) RA-G-308, manufactured by Nippon Seika Co., Ltd. (manufacturing method) (5), (7), (12) and (13) were mixed and dissolved in the aqueous phase in which (3), (4) and (8) to (11) were mixed and dissolved in (1) Those were added, and (6) was added and mixed and dissolved to obtain a vesicle-containing composition.
- the vesicle-containing compositions of Test Examples 2-2 to 2-5 containing 0.001 to 0.2% by mass of the specific anionic surfactant were obtained at 50 ° C., It showed excellent stability at any storage temperature of 10 ° C. In particular, the stability was particularly high in Test Examples 2-3 and 2-4 in which the blending amount of the specific anionic surfactant was 0.005% by mass and 0.1% by mass. On the other hand, in the vesicle-containing compositions of Test Examples 2-1 and 2-6 in which the blending amounts of the specific anionic surfactant were 0.0005% by mass and 0.3% by mass, sufficient stability was not obtained. . From the above results, in the present invention, it is preferable to set the blending amount of the specific anionic surfactant to 0.001 to 0.2% by mass, and particularly 0.005 to 0.1% by mass.
- the specific anionic surfactant sodium stearoylmethyl taurine
- the appearance stability of the vesicle-containing composition obtained by the formulation and manufacturing method shown in Table 3 below was evaluated.
- the evaluation method of the appearance stability is as described above.
- the mixture was dissolved and added, and (6) was added and mixed to obtain a vesicle-containing composition.
- the vesicle-containing compositions of Test Examples 3-2 and 3-3 in which 0.001 to 0.3 mass% of a polar oil (tetraethylhexanoate pentaerythritol) having an IOB of 0.35 was blended, It showed excellent stability.
- a polar oil tetraethylhexanoate pentaerythritol having an IOB of 0.35
- Test Examples 3-1 and 3-4 in which 0.0005% by mass and 0.4% by mass of a polar oil having an IOB of 0.35 were blended, the stability of the vesicles was good although it slightly decreased compared to the above. .
- Test Example 3-5 in which a silicone oil (octamethylcyclotetrasiloxane) was blended instead of the polar oil having an IOB of 0.35 was also excellent in stability.
- Test Examples 3-6 and 3-7 in which diethoxyethyl succinate or nonpolar oil (liquid paraffin) was added instead of the polar oil having an IOB of 0.35, the stability of the vesicles was extremely poor.
- the vesicle-containing compositions of Test Examples 3-8 and 3-9 in which diethoxyethyl succinate or liquid paraffin was used in combination with a polar oil having an IOB of 0.35 showed high stability.
- polar oils having an IOB of 0.80 or less particularly 0.001 to 0.3% by mass with respect to the composition.
- silicone oil is applicable as well as the polar oil.
- polar oils having an IOB of 0.05 to 0.80 can be used.
- formulation example of the vesicle containing composition concerning this invention is given to the following, these do not limit this invention.
- the evaluation method and evaluation criteria of each formulation example were performed according to what was mentioned above.
- Cosmetics containing the vesicle-containing composition were produced according to the formulations and production methods shown in the following "Table 4" to “Table 8", and their odor stability was evaluated.
- the evaluation method of odor stability is as follows.
- a standard product (room temperature 20 ° C., 1-month storage) and a 50 ° C., 1-month storage were evaluated by the smell from a bottle neck of a sample tube by one expert in the odor stability expert panel. Evaluation criteria were as follows. ⁇ : No change in odor relative to the standard product. ⁇ : No change in odor relative to the standard product. ⁇ : A slight change in odor is felt with respect to the standard product. X: An unacceptable change in odor as a cosmetic is felt with respect to the standard product.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
また、特許文献2には、予めシリコーン油と香料とを含む油性成分を混合し、次いで外混合物をシリコーン系界面活性剤のエタノール類溶液に混合し、水性処方と混合してベシクルを形成することによって、香料をベシクルの二分子膜内に保持できることが開示されている。
このように、シリコーン系の界面活性剤によって形成されたベシクルは、その化粧料における実用性についての改善が活発に進められている。
本発明は前記従来技術の課題に鑑みて行われたものであり、水溶性薬剤の存在下で優れた安定性を有するベシクル含有組成物を提供することを目的とする。
すなわち、本発明に係るベシクル含有組成物は、(A)シリコーン系界面活性剤と、(B)ポリオキシエチレンアルキル(12~15)エーテルリン酸、アシルメチルタウリン塩、及びアシルグルタミン酸塩から選択される1種以上のアニオン性界面活性剤を0.001~0.2質量%と、(C)IOBが0.05~0.80の極性油及び/又はシリコーン油と、(D)組成物に対し0.5~5質量%の水溶性薬剤を含む水と、を含有し、(A)シリコーン系界面活性剤がベシクルを形成し、(B)アニオン性界面活性剤が該ベシクルの表面に付着し、(C)極性油及び/又はシリコーン油が該ベシクルの二分子膜内に存在することを特徴とする。
また、前記ベシクル含有組成物において、(D)水溶性薬剤が、トラネキサム酸及びその誘導体、サリチル酸及びその塩類、アルコキシサリチル酸及びその塩類、アスコルビン酸塩及びその誘導体、グリシン及びその誘導体からなる群より選択される1種以上であることが好適である。
また、前記ベシクル含有組成物において、(C)IOB0.05~0.80の極性油及び/又はシリコーン油の配合量が、0.001~0.3質量%であることが好適である。
また、前記ベシクル含有組成物において、(D)組成物に対し0.5~5質量%の水溶性薬剤を含む水が、さらにエタノール、プロピレングリコール、ジプロピレングリコール、1,3-ブチレングリコールからなる群から選択される1種又は2種以上を含有することが好適である。
また、前記製造方法においては、(A)シリコーン系界面活性剤及び(C)IOBが0.05~0.80の極性油及び/又はシリコーン油の混合を行い、(E)ピロ亜硫酸ナトリウム及び/又はジブチルヒドロキシトルエンと(D)水溶性薬剤を含む水と任意の水性成分を混合して得られる混合物と混合し、(B)ポリオキシエチレンアルキル(12~15)エーテルリン酸、アシルメチルタウリン塩、及びアシルグルタミン酸塩から選択される1種以上のアニオン性界面活性剤を添加・混合することが好適である。
本発明にかかるベシクル含有組成物は、(A)シリコーン系界面活性剤と、(B)ポリオキシエチレンアルキル(12~15)エーテルリン酸及びアシルメチルタウリン塩から選択される1種以上のアニオン性界面活性剤を0.001~0.2質量%と、(C)IOBが0.05~0.80の極性油、(D)組成物に対し0.5~5質量%の水溶性薬剤を含む水とを含み、(A)シリコーン系界面活性剤がベシクルを形成し、(B)アニオン性界面活性剤が該ベシクルの表面に付着し、(C)極性油及び/又はシリコーン油が該ベシクルの二分子膜内に存在することを特徴とするものである。
本発明に用いられる(A)シリコーン系界面活性剤は、疎水性基としてポリシロキサン構造を有する界面活性剤であれば、特に限定されるものではない。(A)シリコーン系界面活性剤としては、具体的には、例えば、下記一般式(1)に示すポリオキシアルキレン変性シリコーンが挙げられる。
本発明に使用することのできるアニオン性界面活性剤は、好ましくは下記一般式(2)で表されるポリオキシエチレンアルキル(12~15)エーテルリン酸、アシルメチルタウリン塩及び/又はアシルグルタミン酸塩である。
このようなポリオキシエチレンアルキル(12~15)エーテルリン酸としては、例えば、ポリオキシエチレン(10モル)ラウリルエーテル、ポリオキシエチレン(3モル)ミリスチルエーテル、ポリオキシエチレン(7モル)ドデシルエーテル等が挙げられる。また、市販品として、例えば、DDP-2、NIKKOL TDP-10(いずれも日光ケミカルズ社製)等をいずれも好適に用いることができる。
本発明においては、上記(B)成分として特に、ポリオキシエチレンアルキル(12~15)エーテルリン酸、ステアロイルメチルタウリン塩、ココイルグルタミン酸塩、及びステアロイルグルタミン酸塩から選択される1種以上を用いることが好ましく、市販品としてNIKKOL SMT(日光ケミカルズ社製)、アミソフトCK-22、アミソフトHS-11P(F)(味の素社製)を好適に用いることができる。
本発明では、油性成分として極性油及び/又はシリコーン油を含むことが好適である。中でも、本発明では、IOBが0.05~0.80の極性油及び/又はシリコーン油の配合が好ましい。前記油分を配合せず、IOB値が0.80を超える極性油のみを用いると、ベシクルの安定性が不十分となる。
IOBが0.05~0.80の極性油は、好ましくはIOB値が前記範囲内の油性成分であれば、特に限定されない。なお、油性成分のIOB値については、その構造に基づいて公知の計算方法によって算出することが可能である。
また、不揮発性のシリコーン油としては、特にジフェニルシロキシフェニルトリメチコン、メチルポリシロキサン等の低粘度シリコーン油を用いることが好ましい。
水溶性薬剤
本発明の組成物には、水溶性薬剤を含む水が配合される。シリコーン系界面活性剤によるベシクルは、通常、0.5質量%以上の水溶性薬剤の存在によって安定性が低下してしまうが、本発明においてはベシクルが(B)アニオン性界面活性剤で保護されるため、水溶性薬剤の存在下であっても高い安定性を維持することができる。
本発明にかかるベシクル含有組成物における水溶性薬剤の配合量は、組成物全量に対して0.5~5質量%である。
本発明では、特に、トラネキサム酸及びその誘導体、サリチル酸及びその塩類、アルコキシサリチル酸及びその塩類、アスコルビン酸塩及びその誘導体、グリシン及びその誘導体からなる群より選択されることが好ましい。また、これらの水溶性薬剤は、1種又は2種以上を組みあせて配合することができる。
さらには、特に、トラネキサム酸、トラネキサム酸メチルアミド塩酸塩、4-メトキシサリチル酸カリウム塩、アスコルビン酸グルコシド、エチルビタミンCを含む配合が好ましい。
水の配合量は、特に限定されるものではないが、組成物全量に対して70~95質量%であることが好ましく、さらに好ましくは80~90質量%である。水の配合量が少ないと、ベシクルを形成できない場合がある。
水には上記した水溶性薬剤の他、通常、医薬品や化粧品等に用いられる任意の水性成分が、ベシクルの安定性に影響が出ない範囲の配合量で配合されていてもよい。
特に、前記水性成分としては、ベシクル安定化や使用感の点から、エタノール及びポリオールから選択される1種又は2種以上が配合されることが好ましい。
本発明にかかるベシクル含有組成物のように、シリコーン系界面活性剤を使用してベシクルを製造すると、シリコーン系界面活性剤に由来すると考えられる変臭が生じることがある。このような変臭は、該ベシクル含有組成物に対して、0.001~0.05質量%、好ましくは0.003~0.03質量%のピロ亜硫酸ナトリウム及び/又は0.005~0.05質量%、好ましくは0.01~0.03質量%のジブチルヒドロキシトルエンを配合することによって抑制することができる。
上記の配合量未満では、変臭抑制効果が十分に発揮されず、また、上記の配合量を超えて配合すると、ピロ亜硫酸ナトリウムによる変臭又はジブチルヒドロキシトルエンによる変色が生じる場合がある。
当該効果は、本願発明者により初めて見出された顕著な効果であり、ピロ亜硫酸ナトリウム及び/又はジブチルヒドロキシトルエンは、シリコーン系界面活性剤を使用して製造されるベシクル含有組成物において、シリコーン系界面活性剤に由来する変臭を抑制する変臭抑制剤として機能する。
上記水性処方とシリコーン系界面活性剤とを混合することで、水性相中に上記シリコーン系界面活性剤からなるベシクルが形成され、シリコーン系界面活性剤と混合されていたIOBが0.05~0.80の極性油及び/又はシリコーン油を含む油性成分はベシクルの二分子膜中に取り込まれる。こうして得られたベシクル含有水性溶液中に特定アニオン性界面活性剤を添加すると、該アニオン性界面活性剤は、ベシクル二分子膜の外周囲においてミセルを形成する。このベシクル外周囲に存在する(付着する)ミセルが、ベシクル膜の安定化に大きく寄与しているものと考えられる。なお、前記工程によって予めベシクルが形成されていることから、アニオン性界面活性剤はベシクルの内相に侵入することはできず、アニオン性界面活性剤からなるミセルは実質的に該ベシクルの外相にのみ存在することとなる。
本発明に係る化粧料の用途は特に限定されないが、例えば、化粧水、美容液、ヘアリキッド等として好適に使用することが可能である。
下記表1に示す処方及び製造方法により得た、ベシクル含有組成物についてその外観安定性を評価した。外観安定性の評価方法は下記のとおりである。
ベシクル調製後、及び、50℃及び-10℃下で1ヶ月保存した後の各試験サンプルについて、波長600nmにおける吸光度(Abs.)を吸光光度計(Ubest-55 日本分光株式会社)により測定し、(保存後Abs./調製直後Abs.)として濁度変化(%)を算出し、下記評価基準により外観安定性を評価した。
(外観安定性の評価基準)
◎:濁度変化が5%以下
○:濁度変化が10%未満
△:濁度変化が10~20%
×:濁度変化が20%以上
(*2)CIO、日本サーファクタント工業社製
(製造方法)
(1)に(3)、(4)、(9)~(12)を混合溶解した水相に、(2)に(5)、(8)、(13)、(14)を混合溶解したものを添加し、(6)又は(7)を添加し混合溶解してベシクル含有組成物を得た。
一方、他のアニオン性界面活性剤(POE(2)ラウリルエーテルカルボン酸ナトリウム)を配合した試験例1-3及び1-4のベシクル含有組成物は、前記水溶性薬剤が無配合の場合は安定性を保つことが可能であったが(試験例1-3)、0.5質量%の水溶性薬剤(トラネキサム酸)を配合すると50℃及び-10℃での保存中に白濁してしまい、安定性が悪かった(試験例1-4)。
以上の結果から、本発明において、特定のアニオン性界面活性剤を配合することにより、0.5質量%以上の水溶性薬剤を配合してベシクルの安定性を保持することが可能である。
また、さらに検討を行った結果、本発明においては、水溶性薬剤を組成物全量に対し0.5~5質量%配合できることが明らかとなった。
(*2)RA-G-308、日本精化社製
(製造方法)
(1)に(3)、(4)、(8)~(11)を混合溶解した水相に、(2)に(5)、(7)、(12)、(13)を混合溶解したものを添加し、(6)を添加し混合溶解してベシクル含有組成物を得た。
一方、特定アニオン性界面活性剤の配合量を0.0005質量%及び0.3質量%とした試験例2-1及び2-6のベシクル含有組成物では、十分な安定性が得られなかった。
以上の結果から、本発明において、特定アニオン性界面活性剤の配合量を0.001~0.2質量%、特に0.005~0.1質量%とすることが好適である。
(*2)RA-PE-408、日本精化社製
(製造方法)
(1)に(3)、(4)、(11)~(14)を混合溶解した水相に、(2)に(5)、(7)~(10)、(15)、(16)を混合溶解したものを添加し、(6)を添加し混合溶解してベシクル含有組成物を得た。
また、IOBが0.35の極性油に代えて、シリコーン油(オクタメチルシクロテトラシロキサン)を配合した試験例3-5も安定性に優れていた。
一方、IOBが0.35の極性油に代えて、コハク酸ジエトキシエチル又は非極性油(流動パラフィン)を配合した試験例3-6及び3-7では、ベシクルの安定性が極めて悪かった。
しかしながら、コハク酸ジエトキシエチル又は流動パラフィンをIOBが0.35の極性油と併用した試験例3-8、3-9のベシクル含有組成物は安定性が高かった。
さらに検討を行った結果、本発明においては、IOBが0.05~0.80の極性油を用い得ることが明らかとなった。
(1)に(3)、(4)、(8)~(11)を混合した水相に、(2)に(5)、(7)、(12)、(13)を混合溶解したものを添加し、最後に(6)を添加し混合溶解して化粧水とした。
得られた化粧水は、50℃及び-10℃における濁度変化が5%であり、優れた外観安定性(◎)を示した。
(1)に(3)、(4)、(8)~(11)を混合溶解した水相に、(2)に(5)、(7)、(12)、(13)を混合溶解したものを添加し、最後に(6)を添加し混合溶解して化粧水とした。
得られた化粧水は、50℃及び-10℃における濁度変化が5%であり、優れた外観安定性(◎)を示した。
(1)に、(2)、(4)、(5)、(6)、(11)、(12)、(15)を混合溶解した水相を(7)で中和し、(3)に(8)、(10)、(13)~(15)を混合溶解したものを添加し、最後に(9)を添加し混合溶解して美容液とした。
得られた美容液は、50℃及び-10℃における濁度変化が5%であり、優れた外観安定性(◎)を示した。
(1)に、(3)~(7)及び(11)~(14)を混合溶解した水相に、(2)に(8)、(10)、(15)~(17)を混合溶解したものを添加し、最後に(9)を添加し混合溶解して得られた美容液を不織布に含侵させマスクとした。
得られた美容液は、50℃及び-10℃における濁度変化が5%であり、優れた外観安定性(◎)を示した。
専門パネル1名により、基準品(室温20℃、1ヶ月保存品)と、50℃、1ヶ月保存品を、サンプル管の瓶口からの匂いによって評価した。
なお、評価基準は以下によった。
◎:基準品に対して、匂い変化がない。
○:基準品に対して、匂い変化がほぼない。
△:基準品に対して、匂い変化が僅かに感じられる。
×:基準品に対して、化粧料として許容外の匂い変化が感じられる。
*2:ポリエーテル変性シリコーンの変臭はないがピロ亜硫酸の変臭はあり
(製造方法)
1に、3,4,8,9,10,11を混合溶解した水相に、2に5,7,12,13を混合溶解したものを添加し、最後に6を水で加熱溶解したものを添加し混合溶解して化粧水とした。
(製造方法)
1に、3,4,9,10,11,12,13を混合溶解した水相に、2に5,6,8,14,15を混合溶解したものを添加し、最後に7を添加し混合溶解して化粧水とした。
(製造方法)
1に、3,4,8,9,10,11,12を混合溶解した水相に、2に5,7,13,14を混合溶解したものを添加し、最後に6を添加し混合溶解して化粧水とした。
(製造方法)
1に、2,4,5,6,11,12,13を混合溶解した水相を7で中和し、3に8,10,14,15,16を混合溶解したものを添加し、最後に9を添加し混合溶解して美容液とした。
(製造方法)
1に、3,4,5,6,7,11,12,13,14,15を混合溶解した水相に、2に8,10,16,17,18を混合溶解したものを添加し、最後に9を添加し混合溶解した液を、不織布に含侵させマスクとした。
Claims (9)
- (A)シリコーン系界面活性剤と、
(B)ポリオキシエチレンアルキル(12~15)エーテルリン酸、アシルメチルタウリン塩、及びアシルグルタミン酸塩から選択される1種以上のアニオン性界面活性剤を0.001~0.2質量%と、
(C)IOBが0.05~0.80の極性油及び/又はシリコーン油と、
(D)組成物に対し0.5~5質量%の水溶性薬剤を含む水と、
を含有し、
(A)シリコーン系界面活性剤がベシクルを形成し、(B)アニオン性界面活性剤が該ベシクルの表面に付着し、(C)極性油及び/又はシリコーン油が該ベシクルの二分子膜内に存在することを特徴とするベシクル含有組成物。 - (B)アニオン性界面活性剤が、ポリオキシエチレンアルキル(12~15)エーテルリン酸、ステアロイルメチルタウリン塩、ココイルグルタミン酸塩、及びステアロイルグルタミン酸塩から選択される1種以上であることを特徴とする請求項1に記載のベシクル含有組成物。
- (D)水溶性薬剤が、トラネキサム酸及びその誘導体、サリチル酸及びその塩類、アルコキシサリチル酸及びその塩類、アスコルビン酸塩及びその誘導体、グリシン及びその誘導体からなる群より選択される1種以上であることを特徴とする請求項1又は2に記載のベシクル含有組成物。
- (C)IOBが0.05~0.80の極性油及び/又はシリコーン油の配合量が、0.001~0.3質量%であることを特徴とする請求項1~4のいずれかに記載のベシクル含有組成物。
- (A)シリコーン系界面活性剤により形成されるベシクルが、さらに(E)0.001~0.05質量%のピロ亜硫酸ナトリウム及び/又は0.005~0.05質量%のジブチルヒドロキシトルエンを含有することを特徴とする請求項1~5のいずれかに記載のベシクル含有組成物。
- (D)組成物に対し0.5~5質量%の水溶性薬剤を含む水が、さらに、エタノール、プロピレングリコール、ジプロピレングリコール、1,3-ブチレングリコールからなる群から選択される1種又は2種以上を含有することを特徴とする請求項1~6のいずれかに記載のベシクル含有組成物。
- (A)シリコーン系界面活性剤及び(C)IOBが0.05~0.80の極性油及び/又はシリコーン油の混合を行い、
(D)水溶性薬剤を含む水と混合し、
(B)ポリオキシエチレンアルキル(12~15)エーテルリン酸、アシルメチルタウリン塩、及びアシルグルタミン酸塩から選択される1種以上のアニオン性界面活性剤を添加・混合することを特徴とするベシクル含有組成物の製造方法。 - (A)シリコーン系界面活性剤及び(C)IOBが0.05~0.80の極性油及び/又はシリコーン油の混合を行い、
(E)ピロ亜硫酸ナトリウム及び/又はジブチルヒドロキシトルエンと(D)水溶性薬剤を含む水と任意の水性成分を混合して得られる混合物と混合し、
(B)ポリオキシエチレンアルキル(12~15)エーテルリン酸、アシルメチルタウリン塩、及びアシルグルタミン酸塩から選択される1種以上のアニオン性界面活性剤を添加・混合することを特徴とする請求項8に記載のベシクル含有組成物の製造方法。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES11762708.3T ES2546986T3 (es) | 2010-03-31 | 2011-03-25 | Composición que contiene vesículas |
RU2012144575/04A RU2517710C1 (ru) | 2010-03-31 | 2011-03-25 | Композиция, содержащая везикулы, и способ ее получения |
BR112012024910A BR112012024910A2 (pt) | 2010-03-31 | 2011-03-25 | composição contendo vesícula e método para sua produção |
CN201180016924.5A CN102811708B (zh) | 2010-03-31 | 2011-03-25 | 含有囊泡的组合物 |
US13/637,394 US20130028950A1 (en) | 2010-03-31 | 2011-03-25 | Vesicle-Containing Composition |
KR1020127027086A KR101344557B1 (ko) | 2010-03-31 | 2011-03-25 | 베시클 함유 조성물 |
EP11762708.3A EP2561862B1 (en) | 2010-03-31 | 2011-03-25 | Vesicle-containing composition |
HK13103145.3A HK1175996A1 (en) | 2010-03-31 | 2013-03-13 | Vesicle-containing composition |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-082301 | 2010-03-31 | ||
JP2010082301 | 2010-03-31 | ||
JP2010-220684 | 2010-09-30 | ||
JP2010220684 | 2010-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011122477A1 true WO2011122477A1 (ja) | 2011-10-06 |
Family
ID=44712184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/057378 WO2011122477A1 (ja) | 2010-03-31 | 2011-03-25 | ベシクル含有組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20130028950A1 (ja) |
EP (1) | EP2561862B1 (ja) |
JP (1) | JP4980474B2 (ja) |
KR (1) | KR101344557B1 (ja) |
CN (1) | CN102811708B (ja) |
BR (1) | BR112012024910A2 (ja) |
ES (1) | ES2546986T3 (ja) |
HK (1) | HK1175996A1 (ja) |
RU (1) | RU2517710C1 (ja) |
TW (1) | TWI412378B (ja) |
WO (1) | WO2011122477A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013122102A1 (ja) * | 2012-02-13 | 2013-08-22 | 花王株式会社 | ベシクル組成物の製造方法 |
JP2014019665A (ja) * | 2012-07-18 | 2014-02-03 | Kao Corp | ベシクル組成物の製造方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5988263B2 (ja) * | 2012-09-18 | 2016-09-07 | 国立大学法人京都大学 | 複数の被内包リポソームを内包するリポソーム及びその製造方法 |
JP5690373B2 (ja) * | 2013-04-26 | 2015-03-25 | 株式会社 資生堂 | 水性組成物 |
CN103751072B (zh) * | 2014-02-19 | 2015-04-22 | 珀莱雅化妆品股份有限公司 | 一种能恢复皮肤微生态的非离子表面活性剂囊泡及其制备方法 |
KR101655956B1 (ko) * | 2014-10-30 | 2016-09-08 | 서울과학기술대학교 산학협력단 | 유성 화장품의 제거를 위한 w/o 마이크로에멀전 조성물 |
KR101664877B1 (ko) * | 2015-06-26 | 2016-10-12 | 주식회사 코리아나화장품 | 니트로지방산을 함유하는 니오좀을 포함하는 화장료 조성물 |
CN111263628B (zh) * | 2017-10-26 | 2023-09-08 | 株式会社资生堂 | 含囊泡的组合物 |
ES2896268T3 (es) | 2017-10-27 | 2022-02-24 | Xyon Health Inc | Fórmulas tópicas para el tratamiento de trastornos dermatológicos que incluyen la calvicie de patrón masculino |
CN112165929A (zh) * | 2018-06-06 | 2021-01-01 | 株式会社资生堂 | 使用部分交联或交联型二甲基聚硅氧烷的水包油型乳化化妆品 |
KR20230021435A (ko) | 2021-08-05 | 2023-02-14 | (주)아모레퍼시픽 | 난용성 성분이 안정화된 나노베지클을 포함하는 수중유형 화장료 조성물 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003160476A (ja) * | 2001-09-11 | 2003-06-03 | Kao Corp | 皮膚外用剤 |
JP2007031336A (ja) * | 2005-07-26 | 2007-02-08 | Shiseido Co Ltd | 油中水型皮膚外用剤 |
JP2008024681A (ja) | 2006-07-25 | 2008-02-07 | Shiseido Co Ltd | ベシクル含有組成物及びその製造方法 |
JP2008255109A (ja) * | 2007-03-13 | 2008-10-23 | Kose Corp | ベシクル組成物及び該ベシクル組成物を配合した皮膚外用剤 |
WO2008143140A1 (ja) | 2007-05-15 | 2008-11-27 | Shiseido Company Ltd. | ベシクル含有組成物及びその製造方法 |
JP2009242326A (ja) * | 2008-03-31 | 2009-10-22 | Shiseido Co Ltd | 美白液状化粧料 |
JP2009249360A (ja) * | 2008-04-09 | 2009-10-29 | Shiseido Co Ltd | ベシクル及びそれを含む化粧料 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229104A (en) * | 1991-04-29 | 1993-07-20 | Richardson-Vicks Inc. | Artificial tanning compositions containing positively charged paucilamellar vesicles |
FR2725369B1 (fr) * | 1994-10-07 | 1997-01-03 | Oreal | Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire |
JP3483988B2 (ja) * | 1995-06-01 | 2004-01-06 | 株式会社資生堂 | 皮膚外用剤 |
AU2003293350A1 (en) * | 2002-12-04 | 2004-06-23 | Dow Corning Corporation | Vesicle and microemulsion compositions of polar organic oils based on silicone surfactants |
JP2004269430A (ja) * | 2003-03-10 | 2004-09-30 | Ichimaru Pharcos Co Ltd | 毛髪処理用組成物及び損傷毛用毛髪化粧料 |
EP1746968A2 (en) * | 2004-04-20 | 2007-01-31 | Dow Corning Corporation | Silicone vesicles containing actives |
US8012387B2 (en) * | 2004-04-20 | 2011-09-06 | Dow Corning Corporation | Silicone vesicles |
WO2007053424A2 (en) * | 2005-11-01 | 2007-05-10 | Dow Corning Corporation | Silicone vesicles containing actives |
-
2011
- 2011-03-25 RU RU2012144575/04A patent/RU2517710C1/ru not_active IP Right Cessation
- 2011-03-25 BR BR112012024910A patent/BR112012024910A2/pt not_active IP Right Cessation
- 2011-03-25 CN CN201180016924.5A patent/CN102811708B/zh active Active
- 2011-03-25 KR KR1020127027086A patent/KR101344557B1/ko active IP Right Grant
- 2011-03-25 US US13/637,394 patent/US20130028950A1/en not_active Abandoned
- 2011-03-25 JP JP2011067914A patent/JP4980474B2/ja active Active
- 2011-03-25 ES ES11762708.3T patent/ES2546986T3/es active Active
- 2011-03-25 WO PCT/JP2011/057378 patent/WO2011122477A1/ja active Application Filing
- 2011-03-25 EP EP11762708.3A patent/EP2561862B1/en active Active
- 2011-03-29 TW TW100110716A patent/TWI412378B/zh not_active IP Right Cessation
-
2013
- 2013-03-13 HK HK13103145.3A patent/HK1175996A1/xx not_active IP Right Cessation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003160476A (ja) * | 2001-09-11 | 2003-06-03 | Kao Corp | 皮膚外用剤 |
JP2007031336A (ja) * | 2005-07-26 | 2007-02-08 | Shiseido Co Ltd | 油中水型皮膚外用剤 |
JP2008024681A (ja) | 2006-07-25 | 2008-02-07 | Shiseido Co Ltd | ベシクル含有組成物及びその製造方法 |
JP2008255109A (ja) * | 2007-03-13 | 2008-10-23 | Kose Corp | ベシクル組成物及び該ベシクル組成物を配合した皮膚外用剤 |
WO2008143140A1 (ja) | 2007-05-15 | 2008-11-27 | Shiseido Company Ltd. | ベシクル含有組成物及びその製造方法 |
JP2009242326A (ja) * | 2008-03-31 | 2009-10-22 | Shiseido Co Ltd | 美白液状化粧料 |
JP2009249360A (ja) * | 2008-04-09 | 2009-10-29 | Shiseido Co Ltd | ベシクル及びそれを含む化粧料 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2561862A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013122102A1 (ja) * | 2012-02-13 | 2013-08-22 | 花王株式会社 | ベシクル組成物の製造方法 |
JP2014019665A (ja) * | 2012-07-18 | 2014-02-03 | Kao Corp | ベシクル組成物の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
TWI412378B (zh) | 2013-10-21 |
BR112012024910A2 (pt) | 2016-07-05 |
EP2561862A4 (en) | 2013-10-30 |
CN102811708B (zh) | 2014-11-05 |
HK1175996A1 (en) | 2013-07-19 |
EP2561862B1 (en) | 2015-08-05 |
JP4980474B2 (ja) | 2012-07-18 |
KR101344557B1 (ko) | 2013-12-26 |
US20130028950A1 (en) | 2013-01-31 |
KR20130040829A (ko) | 2013-04-24 |
JP2012092084A (ja) | 2012-05-17 |
CN102811708A (zh) | 2012-12-05 |
RU2517710C1 (ru) | 2014-05-27 |
TW201201849A (en) | 2012-01-16 |
ES2546986T3 (es) | 2015-09-30 |
EP2561862A1 (en) | 2013-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4980474B2 (ja) | ベシクル含有組成物 | |
US8313755B2 (en) | Clear aqueous ceramide composition | |
JP7411709B2 (ja) | 水中油型乳化組成物 | |
US20120164357A1 (en) | External Preparation | |
JP2011195510A (ja) | 水中油型乳化皮膚外用組成物 | |
KR101492290B1 (ko) | 베시클 조성물, 및 피부 외용제 | |
KR101593382B1 (ko) | 수성 조성물 | |
JP5024937B2 (ja) | 経皮吸収促進剤及びこれを含有する皮膚外用剤 | |
JP2010189351A (ja) | 経皮吸収促進剤及びこれを含有する皮膚外用剤 | |
JP2010189281A (ja) | 水中油型乳化組成物 | |
JP3865300B2 (ja) | 経皮吸収促進剤及びこれを含有する皮膚外用剤 | |
JP6747763B2 (ja) | 乳化化粧料 | |
JP2012036119A (ja) | 水中油型乳化組成物 | |
TW202308591A (zh) | 化妝料 | |
JP2010189352A (ja) | 経皮吸収促進剤及びこれを含有する皮膚外用剤 | |
JP2003267830A (ja) | 液状化粧料 | |
WO2010110048A1 (ja) | 可溶化組成物 | |
JPH08183725A (ja) | 皮膚化粧料 | |
JPH11279023A (ja) | 外用組成物 | |
CN117157052A (zh) | 含有囊泡的化妆料 | |
WO2023106121A1 (ja) | 水中油型乳化化粧料 | |
CN118338885A (zh) | 化妆品 | |
CN116249509A (zh) | 囊泡组合物及其制造方法、以及包含囊泡组合物的化妆料基剂 | |
JP2013213171A (ja) | 新規なシリコーン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180016924.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11762708 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13637394 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1201005155 Country of ref document: TH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20127027086 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011762708 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012144575 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012024910 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012024910 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120928 |